Medtronic Set To Compete With Abbott/St Jude In VADs After Buying HeartWare
This article was originally published in Clinica
HeartWare has found a way to pay for the expanded commercialization of its HVAD ventricular assist device and the development of its MVAD miniaturized ventricular assist device; the Boston-area VAD-maker has agreed be acquired by medtech giant Medtronic for $1.1bn in cash.
You may also be interested in...
HeartMate and Medtronic’s HeartWare ventricular assist device platforms have been tagged with class I recalls in the last few weeks based on separate safety issues.
The expanded labeling gives Medtronic's HVAD, acquired when it bought HeartWare last summer, the same indication as Abbott's HeartMate II ventricular assist device.
Abbott Laboratories accounted for two of five original PMA approvals recorded by US FDA in August. That update and more from Medtech Insight's Approvals Tracker.